Scynexis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-6.9%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.91next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Investments Quarterly72.4MTarget: Sufficient to fund operations into mid-2029
SCY-247 Phase 1 IV Formulation Study Topline Data AnnuallyTarget: Release topline data in H2 2026
SCY-770 Phase 2 Proof-of-Concept Study Initiation AnnuallyTarget: Initiate study in Q4 2026
Watch Items
- GSK BREXAFEMME (ibrexafungerp) Relaunch Regulatory InteractionsTrigger: FDA feedback or official relaunch timeline announcement by GSKAction: Assess potential timing of up to $145.5 million in annual net sales milestones and low-to-mid single-digit royalties.
- SCY-247 Phase 2 Proof-of-Concept Study in Invasive CandidiasisTrigger: First patient dosed in Phase 2 studyAction: Monitor clinical progress and safety profile of the second-generation fungerp candidate.
Research as of 20 Jun 2026